Henri Termeer

Henri Termeer. A pioneering biotechnology executive, Henri Termeer is best known for his transformative, patient-centric leadership of the biopharmaceutical company Genzyme. Under his tenure, the firm became a global leader in developing treatments for rare diseases, most notably for Gaucher's disease with the drug Cerezyme. His innovative approach to drug pricing and patient access programs fundamentally reshaped the biotechnology industry and left a lasting legacy in orphan drug development.

Early life and education

Born in Rotterdam in the aftermath of World War II, Henri Termeer was raised in the Netherlands. He pursued his higher education at Erasmus University Rotterdam, where he earned a degree in economics. His early professional path led him to the multinational corporation Baxter International, where he held various positions in Europe and the United States. This experience in the healthcare industry and international business provided a critical foundation for his future career in the emerging field of biotechnology.

Career at Genzyme

Termeer joined Genzyme in 1983 as its president, assuming the roles of Chief Executive Officer and Chairman two years later. At the time, the Cambridge-based company was a small startup focused on enzyme research. Termeer spearheaded its strategic pivot toward developing therapies for lysosomal storage disorders, a group of severe genetic conditions. His most significant achievement was the development and 1991 FDA approval of Cerezyme (imiglucerase), a recombinant DNA therapy for Gaucher's disease. He also championed the creation of Myozyme (alglucosidase alfa) for Pompe disease, further establishing Genzyme's dominance in the orphan drug market.

Leadership and business philosophy

Termeer’s leadership was defined by a deeply held belief that a biotechnology company’s success was intrinsically linked to serving patients. He instituted novel patient assistance programs and pioneered a controversial high-price model for Cerezyme, arguing that the cost reflected the value of transforming a fatal disease into a manageable condition and funded future research and development. This model, alongside his focus on personalized medicine for small patient populations, became a blueprint for the modern biopharmaceutical sector. His management style fostered a unique corporate culture at Genzyme that emphasized long-term vision over short-term shareholder gains.

Later career and board memberships

After Sanofi acquired Genzyme in 2011, Termeer departed the company. He remained highly active, leveraging his expertise through roles on numerous corporate and philanthropic boards. He served as a director for several leading life sciences companies, including Vertex Pharmaceuticals, Ariad Pharmaceuticals, and Verastem. Beyond corporate boards, he contributed his guidance to academic and research institutions such as the Massachusetts Institute of Technology and the Dana–Farber Cancer Institute. He also co-founded the Termeer Foundation, which continues to support innovators in the biotechnology field.

Legacy and honors

Henri Termeer is widely regarded as a visionary who helped define the biotechnology industry. His patient-focused model for developing orphan drugs demonstrated that targeting rare diseases could be both medically impactful and commercially viable, inspiring a generation of companies. His contributions were recognized with numerous honors, including the Biotechnology Innovation Organization’s Biotechnology Heritage Award. The Massachusetts Biotechnology Council also presents an annual award in his name. Termeer’s legacy endures through the thousands of patients treated with therapies he helped bring to market and the entrepreneurial spirit he championed in Boston and beyond.

Category:Dutch businesspeople Category:Biotechnology businesspeople Category:1946 births Category:2017 deaths